Iovance Biotherapeutics Welcomes Dan Kirby as Chief Commercial Officer

Iovance Biotherapeutics has named Dan Kirby as its new Chief Commercial Officer, marking a significant step in its mission to advance tumor-infiltrating lymphocyte (TIL) therapy. With a strong background in leading commercial strategies for cell therapy, Kirby has previously held key leadership roles at Celgene, Juno Therapeutics, Amgen, and most recently, Orca Bio. His appointment comes at a pivotal time as Iovance continues the U.S. launch of Amtagvi and expands Proleukin sales into new global markets.

Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance, expressed excitement about Kirby’s appointment, emphasizing his extensive expertise in cell therapy commercialization. Kirby, in turn, shared his enthusiasm for joining Iovance, stating that the company is well-positioned to lead the future of TIL cell therapy for solid tumor cancers. His leadership is expected to accelerate market adoption and reinforce Iovance’s role as a pioneer in the field.